Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Condition: Primary Central Nervous System Lymphoma Intervention: Drug: Camrelizumab Sponsor: Beijing Sanbo Brain Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials